KNSA Nasdaq· Kiniksa Pharmaceuticals, Ltd.
FundamentalsNews digest Peer analysis
KNSA Nasdaq· Kiniksa Pharmaceuticals, Ltd.
Earnings report Q4 2023

KNSA Reports Significant Increase in Revenue in Latest Quarter

Segments of revenue

In the latest quarter, KNSA reported total revenue of $270.3 million, representing a substantial increase compared to the previous year's revenue of $220.2 million. This growth can be attributed to a surge in product revenue, which reached $233.2 million, more than doubling the previous year's figure of $122.5 million. Additionally, the company generated $37.1 million in license and collaboration revenue during the quarter.


KNSA's financial performance in the latest quarter showcases several strengths. The significant increase in product revenue can be attributed to the successful commercialization of their pharmaceutical products. This indicates a strong demand for their offerings in the market. Furthermore, the company's management has effectively pursued collaborations and licensing agreements, resulting in a substantial boost in revenue from these sources.


Despite the positive revenue growth, KNSA faced challenges in managing its operating expenses. The company's total operating expenses for the quarter amounted to $295.5 million, surpassing the previous year's expenses of $210.4 million. This increase can be attributed to higher costs of goods sold, collaboration expenses, research and development, and selling, general, and administrative expenses. Managing these expenses efficiently will be crucial for the company's profitability in the future.


It is worth mentioning that KNSA reported a net income of $14.1 million in the latest quarter, a significant improvement compared to the net loss of $157.9 million in the previous year. This positive turnaround can be attributed to the increase in revenue and effective cost management. Additionally, the company's Class A common shares are listed on The Nasdaq Global Select Market.


KNSA demonstrated a strong performance in the latest quarter, with a substantial increase in revenue primarily driven by the growth in product revenue and successful collaborations. The company's ability to generate a net income after reporting losses in the previous year is noteworthy. However, KNSA needs to address the challenge of managing its operating expenses to ensure sustained profitability in the future. Overall, the company's financial performance indicates positive momentum and potential for further growth.

Source documents

Form 10-K  filed on Feb 28, 2024
23 pages scanned

Reference data

Company financials Q4 revenue 83.4M
Analyst estimates Q4 EPS missed by -318.75%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.